You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ovarian cancer, Platinum-sensitive, PARP inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor Trial in Seoul

Recruiting
  • Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Jul 6, 2021

Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

Active, not recruiting
  • Fallopian Tube Endometrioid Tumor
  • +13 more
  • Orange, California
  • +19 more
Jan 10, 2023

Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer Trial in Czechia, Poland (RP12146)

Recruiting
  • Solid Tumor
  • +6 more
  • HoĊ™ovice, Czechia
  • +5 more
Jun 8, 2022

Ovarian Cancer Trial in Villejuif (AsiDNA, Niraparib, Olaparib)

Recruiting
  • Ovarian Cancer
  • Villejuif, Val De Marne, France
    Gustave Roussy
Sep 27, 2021

Advanced Pancreatic Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 Trial in

Recruiting
  • Advanced Pancreatic Carcinoma
  • +27 more
  • Gainesville, Florida
  • +3 more
Jan 3, 2023

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Ovarian Cancer Trial (JPI-547)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 24, 2022

Relapsed Ovarian Cancer Trial (Fluzoparib, Apatinib)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Oct 7, 2023

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Relapsed Ovarian Cancer Trial (Fluzoparib+Apatinib, Fluzoparib Monotherapy)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Jul 27, 2022

Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

Recruiting
  • Ovarian Cancer
  • fluzopanib and bevacizumab
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Sep 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 11, 2022

Ovarian Cancer, Drug Related Tumor/Cancer Trial (secondary cytoreductive surgery, chemo)

Not yet recruiting
  • Ovarian Cancer
  • Drug Related Neoplasm/Cancer
  • (no location specified)
Jan 28, 2023

High Grade Serous Carcinoma Trial in Baltimore, Boston, Philadelphia (Olaparib Pill, AZD6738)

Recruiting
  • High Grade Serous Carcinoma
  • Baltimore, Maryland
  • +2 more
Mar 4, 2022

Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)

Not yet recruiting
  • Ovarian Cancer
  • Malignant Neoplasm of Uterus
  • New York, New York
    Icahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023

Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemo, Platinum Sensitive Trial in China,

Active, not recruiting
  • Relapsed Ovarian Cancer
  • +2 more
  • Olaparib 300mg tablets
  • Beijing, China
  • +24 more
Dec 5, 2022

Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Cetntre
Sep 25, 2023

Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 20, 2023

Bespoke ctDNA Assay for Recurrence and Treatment Response

Recruiting
  • Ovarian Cancer
  • platinum-sensitive EOC
  • platinum-resistant and rEOC
  • Shanghai, Shanghai, China
    Hao Wen
Jul 5, 2022

Breast Cancer After Ovarian Cancer During and/or After Therapy:

Recruiting
  • BRCA-Associated Breast Carcinoma
  • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mar 9, 2023